225385-03-5

Basic information

• Product Name: Thieno[3,2-d]pyrimidine,6-bromo-4-chloro-
• Synonyms: 6-Bromo-4-chlorothieno[3,2-d]pyrimidine
• CAS NO: 225385-03-5
• Molecular Formula: C₆H₂BrClN₂S
• Molecular Weight: 249.5155
• EINECS: 635-520-2
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 225385-03-5.mol

Chemical Properties

• Boiling Point: 345.5oC at 760 mmHg
• Flash Point: 162.7oC
• Appearance: /
• Density: 1.955
• Vapor Pressure: 0.000123mmHg at 25°C
• Refractive Index: 1.735
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.19±0.40(Predicted)
• CAS DataBase Reference: Thieno[3,2-d]pyrimidine,6-bromo-4-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[3,2-d]pyrimidine,6-bromo-4-chloro-(225385-03-5)
• EPA Substance Registry System: Thieno[3,2-d]pyrimidine,6-bromo-4-chloro-(225385-03-5)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 225385-03-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
Thieno[3,2-d]pyrimidine,6-bromo-4-chlorois used as a building block for the synthesis of novel pharmaceutical compounds due to its unique molecular structure and potential biological activities. It can contribute to the development of new drugs with specific therapeutic effects.
Used in Drug Development:
In the field of drug development, Thieno[3,2-d]pyrimidine,6-bromo-4-chlorois utilized as a research tool in chemical biology. Its unique structure allows for the exploration of its interactions with biological systems, potentially leading to the discovery of new therapeutic agents or mechanisms of action.
Used in Chemical Biology Research:
Thieno[3,2-d]pyrimidine,6-bromo-4-chlorois employed as a research tool in chemical biology to study its interactions with biological systems. This can provide insights into its potential biological activities and help in understanding its role in various biological processes.
Used in Pharmaceutical Compound Synthesis:
In the synthesis of pharmaceutical compounds, Thieno[3,2-d]pyrimidine,6-bromo-4-chlorois used as a key component to create new drugs with specific therapeutic properties. Its unique structure allows for the development of compounds with targeted effects on various diseases and conditions.

InChI:InChI=1/C6H2BrClN2S/c7-4-1-3-5(11-4)6(8)10-2-9-3/h1-2H

Upstream product

• 124-73-2 1,2-dibromo-1,1,2,2-tetrafluoroethane 
• 16269-66-2 4-chlorothieno[3,2-d]pyrimidine 
• 4111-54-0 lithium diisopropyl amide 
• 16285-69-1 3-(formylamino)-2-thiophenecarboxylic acid methyl ester 
• 16234-10-9 3H-thieno[3,2-d]pyrimidin-4-one 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 

Downstream Products

• 552295-33-7 6-bromo-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)thieno[3,2-d]pyrimidin-4-amine 
• 1228102-70-2 6-bromo-N-(3-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidin-4-amine 
• 1228102-79-1 3-(4-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)benzaldehyde 
• 1228103-15-8 N-(3-(4-methoxybenzyloxy)phenyl)-6-(5-(pyrrolidin-1-ylmethyl)thiophen-2-yl)thieno[3,2-d]pyrimidin-4-amine 
• 1228102-08-6 3-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-ylamino)-phenol 
• 1228101-19-6 (3-methoxyphenyl)-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-amine 
• 1228101-09-4 3-[6-(4-methoxyphenyl)-thieno[3,2-d]pyrimidin-4-ylamino]-phenol 
• 1228101-07-2 3-(6-bromo-thieno[3,2-d]pyrimidin-4-ylamino)-phenol 
• 1228102-81-5 5-(4-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)thiophene-2-carboxaldehyde 
• 1228102-80-4 6-(5-(1,3-dioxolane-2-yl)thiophen-2-yl)-N-(3-(4-methoxybenzyloxy)phenyl)thieno[3,2-d]pyrimidin-4-amine 

Relevant articles and documents

Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria

Target repurposing is a proven method for finding new lead compounds that target Trypanosoma brucei, the causative agent of human African trypanosomiasis. Due to the recent discovery of a lapatinib-derived analog 2 with excellent potency against T. brucei (EC50 = 42 nM) and selectivity over human host cells, we have explored other classes of human tyrosine kinase inhibitor scaffolds in order to expand the range of chemotypes for pursuit. Following library expansion, we found compound 11e to have an EC50 of 84 nM against T. brucei cells while maintaining selectivity over human hepatocytes. In addition, the library was tested against causative agents of Chagas' disease, leishmaniasis, and malaria. Two analogs with sub-micromolar potencies for T. cruzi (4j) and Plasmodium falciparum (11j) were discovered, along with an analog with considerable potency against Leishmania major amastigotes (4e). Besides identifying new and potent protozoan growth inhibitors, these data highlight the value of concurrent screening of a chemical library against different protozoan parasites. This journal is

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors

We report here the synthesis and SAR of a new series of thieno[3,2-d]pyrimidines as potent Tpl2 kinase inhibitors. The proposed binding mode suggests the potential flipped binding mode depending on the substitution. Biacore studies show evidence of binding of these molecules to the protein kinase. The kinome inhibition profile of these molecules suggests good selectivity.

INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR

The present invention relates to indolylalkylthienopyhmidylamines of the general formula (I), to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP2

THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR

The present invention relates to thienopyrimidylamines of the general formula (I), to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP2

N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are N-arylalkyl-thienopyrimidin-4-amines and analogs thereof, represented by the Formula I: wherein Ar, R1, R3, R4, R10-R12 and n are defined herein. The present invention relates to the dis

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity

Novel classes of thienopyrimidines and thienopyridines have been identified as potent inhibitors of VEGFR-2 kinase. The synthesis and SAR of these compounds is presented, along with successful efforts to diminish EGFR activity present in the lead series.

Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2and R11are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.